The Journal of clinical endocrinology and metabolism
-
J. Clin. Endocrinol. Metab. · Feb 2017
Randomized Controlled TrialGlycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study.
Previous studies have shown a relationship between glycemic control and posttransplant morbidity. ⋯ Glycemic control of 140 mg/dL safely resulted in a reduced incidence of infection after transplantation compared with 180 mg/dL, but with an increase in moderate hypoglycemia.
-
J. Clin. Endocrinol. Metab. · Feb 2017
Cortical Bone Area Predicts Incident Fractures Independently of Areal Bone Mineral Density in Older Men.
Areal bone mineral density (aBMD) measured using dual-energy X-ray absorptiometry (DXA) is used clinically to predict fracture but does not discriminate between trabecular and cortical bone assessment. ⋯ HR-pQCT measurement of cortical area and mass might add clinically useful information for the evaluation of fracture risk.
-
J. Clin. Endocrinol. Metab. · Feb 2017
Case ReportsSevere Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Denosumab inhibits bone resorption, increases bone mineral density, and reduces fracture risk. Denosumab was approved for the treatment of osteoporosis and the prevention of bone loss in some oncological situations. Denosumab discontinuation is associated with a severe bone turnover rebound (BTR) and a rapid loss of bone mineral density. The clinical consequences of the BTR observed after denosumab discontinuation are not known. ⋯ Studies are urgently needed to determine 1) the pathophysiological processes involved, 2) the clinical profile of patients at risk for RAVFs, and 3) the management and/or treatment regimens after denosumab discontinuation. Health authorities, physicians, and patients must be aware of this RAVF risk. Denosumab injections must be scrupulously done every 6 months but not indefinitely.